KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) Equity Ratio: 2013-2025

Historic Equity Ratio for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to 0.92.

  • Xenon Pharmaceuticals' Equity Ratio fell 3.56% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year decrease of 3.56%. This contributed to the annual value of 0.95 for FY2024, which is 1.66% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Equity Ratio is 0.92, which was down 2.10% from 0.94 recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Equity Ratio ranged from a high of 0.97 in Q2 2022 and a low of 0.92 during Q3 2025.
  • For the 3-year period, Xenon Pharmaceuticals' Equity Ratio averaged around 0.95, with its median value being 0.95 (2023).
  • Its Equity Ratio has fluctuated over the past 5 years, first rose by 19.86% in 2021, then declined by 3.56% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.96 in 2021, then decreased by 0.51% to 0.96 in 2022, then grew by 0.53% to 0.96 in 2023, then decreased by 1.66% to 0.95 in 2024, then declined by 3.56% to 0.92 in 2025.
  • Its Equity Ratio stands at 0.92 for Q3 2025, versus 0.94 for Q2 2025 and 0.95 for Q1 2025.